Translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer

Celsius Therapeutics is charting a new course of target and drug discovery by understanding the specific cells, among many others, that are causing the disease and by identifying the genes that are triggering their malfunction. Celsius is applying a systematic approach to single-cell sequencing, combining massive datasets and complex algorithms in order to discover first-in-class precision therapies that have a transformative impact on the lives of patients with autoimmune diseases and cancer.

Year Invested: 2018
Location: Cambridge, MA

Recent News

May 15, 2018
Celsius Therapeutics Launches with $65 Million in Series A Financing to Develop Precision Therapeutics For People with Autoimmune Diseases and Cancer

Read More News

Associated Team Members

Alexis Borisy

Jason Coloma, Ph.D.
Venture Partner

Christoph Lengauer, Ph.D.

Melissa McCracken, Ph.D.
Senior Associate

Kelly Moynihan, Ph.D.
Senior Associate